Individual host factors associated with Onchocerca volvulus microfilarial densities 15, 80 and 180 days after a first dose of ivermectin

Acta Tropica

Volumn 120, Issue SUPPL. 1, 2011, Pages

  Pion, Sébastien D S ^a   Grout, Lise ^b   Kamgno, Joseph ^c   Nana Djeunga, Hugues ^c   Boussinesq, Michel ^a  

^a INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^b DRASS Midi Pyrénées   (France)

^c UNIVERSITY OF YAOUNDÉ I   (Cameroon)

Author keywords

Efficacy; Inter individual variability; Ivermectin; Onchocerca volvulus; Onchocerciasis; Resistance

Indexed keywords

IVERMECTIN;

DISEASE TREATMENT; DRUG; DRUG RESISTANCE; ENDEMISM; HOST-PARASITE INTERACTION; MAXIMUM LIKELIHOOD ANALYSIS; NEMATODE; ONCHOCERCIASIS; POPULATION DENSITY;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CAMEROON; CHILD; DRUG EFFICACY; ENDEMIC DISEASE; FEMALE; GENDER; HUMAN; MALE; ONCHOCERCA VOLVULUS; ONCHOCERCIASIS; PARASITE PHENOMENA AND FUNCTIONS; PRESCHOOL CHILD; SCHOOL CHILD; SKIN MICROFILARIAL DENSITY; SKIN NODULE;

ADOLESCENT; ADULT; AGE FACTORS; ANIMALS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE; FEMALE; FILARICIDES; HOST-PATHOGEN INTERACTIONS; HUMANS; IVERMECTIN; MALE; MICROFILARIA; ONCHOCERCA VOLVULUS; ONCHOCERCIASIS; SEX FACTORS; SKIN; TREATMENT OUTCOME; YOUNG ADULT;

CAMEROON;

ONCHOCERCA VOLVULUS;

EID: 80054033652     PISSN: 0001706X     EISSN: 18736254     Source Type: Journal    
DOI: 10.1016/j.actatropica.2010.05.004     Document Type: Article

References (58)

1. Ali M.M.M., Mukhtar M.M., Baraka O.Z., Homeida M.M.A., Kheir M.M., Mackenzie C.D. Immunocompetence may be important in the effectiveness of Mectizan® (ivermectin) in the treatment of human onchocerciasis. Acta Trop. 2002, 84:49-53.
2. Awadzi K., Dadzie K.Y., Schulz-Key H., Haddock D.R.W., Gilles H.M., Aziz M.A. The chemotherapy of onchocerciasis. X. An assessment of four single dose treatment regimes of MK-933 (ivermectin) in human onchocerciasis. Ann. Trop. Med. Parasitol. 1985, 79:63-78.
3. Awadzi K., Boakye D.A., Edwards G., Opoku N.O., Attah S.K., Osei-Atweneboana M.Y., Lazdins-Helds J.K., Ardrey A.E., Addy E.T., Quartey B.T., Ahmed K., Boatin B.A., Soumbey-Alley E.W. An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann. Trop. Med. Parasitol. 2004, 98:231-249.
4. Baraka O.Z., Mahmoud B.M., Marschke C.K., Geary T.G., Homeida M.M.A., Williams J.F. Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus. Eur. J. Clin. Pharmacol. 1996, 50:407-410.
5. Barnes E.H., Dobson R.J., Barger I.A. Worm control and anthelmintic resistance: adventures with a model. Parasitol. Today 1995, 11:56-63.
6. Basáñez M.G., Pion S.D.S., Boakes E., Filipe J.A.N., Churcher T.S., Boussinesq M. Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis. Lancet Infect. Dis. 2008, 8:310-322.
7. Bourguinat C., Pion S.D.S., Kamgno J., Gardon J., Duke B.O.L., Boussinesq M., Prichard R.K. Genetic selection of low fertile Onchocerca volvulus by ivermectin treatment. PLoS Negl. Trop. Dis. 2007, 1:e72.
8. Bourguinat C., Ardelli B.F., Pion S.D.S., Kamgno J., Gardon J., Duke B.O.L., Boussinesq M., Prichard R.K. P-glycoprotein-like protein, a possible genetic marker for ivermectin resistance selection in Onchocerca volvulus. Mol. Biochem. Parasitol. 2008, 158:101-111.
9. Boussinesq M., Prod'hon J., Chippaux J.P., Quillévéré D. Effet à long terme d'une prise unique d'ivermectine sur les charges microfilariennes dermiques dans un foyer d'onchocercose du Nord-Cameroun. Ann. Soc. Belge Med. trop. 1993, 73:189-196.
10. Boussinesq M., Gardon J., Kamgno J., Demanga-Ngangue, Pion S.D.S., Duke B.O.L. Studies on the macrofilarial population of Onchocerca volvulus in hyper-endemic villages of the central province of Cameroon. Ann. Trop. Med. Parasitol. 2001, 95:379-388.
11. Brattig N.W., Lepping B., Timmann C., Büttner D.W., Marfo Y., Hamelmann C., Horstmann R.D. Onchocerca volvulus-exposed persons fail to produce interferon-γ in response to O. volvulus antigen but mount proliferative responses with interleukin-5 and IL-13 production that decrease with increasing microfilarial density. J. Infect. Dis. 2002, 185:1148-1154.
12. Chavasse D.C., Post R.J., Lemoh P.A., Whitworth J.A.G. The effect of repeated doses of ivermectin on adult female Onchocerca volvulus in Sierra Leone. Trop. Med. Parasitol. 1992, 43:256-262.
13. Churcher T.S., Pion S.D.S., Osei-Atweneboana M.Y., Prichard R.K., Awadzi K., Boussinesq M., Collins R.C., Whitworth J.A., Basáñez M.G. Identifying sub-optimal responses to ivermectin in the treatment of river blindness. Proc. Natl Acad. Sci. U.S.A. 2009, 106:16716-16726.
14. Cooper P.J., Mancero T., Espinel M., Sandoval C., Lovato R., Guderian R.H., Nutman T.B. Early human infection with Onchocerca volvulus is associated with an enhanced parasite-specific cellular immune response. J. Infect. Dis. 2001, 183:1662-1668.
15. Cupp E., Richards F., Lammie P., Eberhard M. Efficacy of ivermectin against Onchocerca volvulus in Ghana. Lancet 2007, 370:1123.
16. Darge K., Lucius R., Monson M.H., Behrendsen J., Büttner D.W. Immunohistological and electron microscopic studies of microfilariae in skin and lymph nodes from onchocerciasis patients after ivermectin treatment. Trop. Med. Parasitol. 1991, 42:361-367.
17. De Sole G., Remme J., Awadzi K., Accorsi S., Alley E.S., Ba O., Dadzie K.Y., Giese J., Karam M., Keita F.M. Adverse reactions after large-scale treatment of onchocerciasis with ivermectin: combined results from eight community trials. Bull. World Health Organ. 1989, 67:707-719.
18. Duerr H.P., Dietz K., Büttner D.W., Schulz-Key H. A stochastic model for the aggregation of Onchocerca volvulus in nodules. Parasitology 2001, 123:193-201.
19. Duerr H.P., Dietz K., Schulz-Key H., Büttner D.W., Eichner M. The relationships between the burden of adult parasites, host age and the microfilarial density in human onchocerciasis. Int. J. Parasitol. 2004, 34:463-473.
20. Duke B.O.L., Anderson J., Fuglsang H. The Onchocerca volvulus transmission potentials and associated patterns of onchocerciasis at four Cameroon Sudan-savanna villages. Tropenmed Parasitol. 1975, 26:143-154.
21. Duke B.O.L., Zea-Flores G., Muñoz B. The embryogenesis of Onchocerca volvulus over the first year after a single dose of ivermectin. Trop. Med. Parasitol. 1991, 42:175-180.
22. Eng J.K.L., Prichard R.K. A comparison of genetic polymorphism in populations of Onchocerca volvulus from untreated- and ivermectin-treated patients. Mol. Biochem. Parasitol. 2005, 142:193-202.
23. Etya'ale D. Vision 2020: update on onchocerciasis. Community Eye Health 2001, 14(38):19-21.
24. Fendt J., Hamm D.M., Banla M., Schulz-Key H., Wolf H., Helling-Giese G., Heuschkel C., Soboslay P.T. Chemokines in onchocerciasis patients after a single dose of ivermectin. Clin. Exp. Immunol. 2005, 142:318-326.
25. Fulford A.J.C., Macfarlane S.B.J., Awadzi K., Bell D.R., Gilles H.M. The chemotherapy of onchocerciasis. XII. The prediction of microfilarial loads in patients with onchocerciasis after treatment with diethylcarbamazine in Northern Ghana. Ann. Trop. Med. Parasitol. 1987, 81:701-711.
26. Geerts S., Gryseels B. Drug resistance in human helminths: current situation and lessons from livestock. Clin. Microbiol. Rev. 2000, 13:207-222.
27. González Canga A., Sahagún Prieto A., Diez Liébana M., Fernández Martínez N., Sierra Vega M., García Vieitez J. The pharmacokinetics and interactions of ivermectin in humans-a mini-review. AAPS J. 2008, 10:42-46.
28. Guzzo C.A., Furtek C.I., Porras A.G., Chen C., Tipping R., Clineschmidt C.M., Sciberras D.G., Hsieh J.Y.K., Lasseter K.C. Safety, tolerability, and pharmacokinetics of escalading high doses of ivermectin in healthy adult subjects. J. Clin. Pharmacol. 2002, 42:1122-1133.
29. Hoerauf A., Brattig N. Resistance and susceptibility in human onchocerciasis-beyond Th1 vs Th2. Trends Parasitol. 2002, 18:25-31.
30. Kebede A., Taticheff S., Bulto T., Workneh W., Tilahun D. Effect of ivermectin treatment on microfilarial load in patients with Onchocerca volvulus in Bebeka, Ethiopia. Ethiop. Med. J. 1993, 31:127-135.
31. Kipp W., Bamhuhiiga J. Validity of nodule palpation in a Simulium neavei-transmitted onchocerciasis area in Uganda. Am. J. Trop. Med. Hyg. 2002, 67:128-131.
32. Larivière M., Beauvais B., Aziz M., Garin Y.J.F., Abeloos J., Derouin F., Bamba M., Ferly-Therizol M., Sarfati C., Basset D., Basset A., Toure Y., Song D., Gaxotte P. Etude en Côte d'Ivoire (1985-1987) de l'efficacité et de la tolérance de l'ivermectine (Mectizan®) dans l'onchocercose humaine. II. Evaluation, en vue de campagnes de masse, des effets de l'administration annuelle ou semestrielle de doses uniques orales de 100, 150 ou 200 mcg/kg. Bull. Soc. Pathol. Exot. 1989, 82:48-57.
33. Lespine A., Dupuy J., Alvinerie M., Comera C., Nagy T., Krajcsi P., Orlowski S. Interaction of macrocyclic lactones with the multidrug transporters: the bases of the pharmacokinetics of lipid-like drugs. Curr. Drug Metab. 2009, 10:272-288.
34. Lifschitz A., Ballent M., Virkel G., Sallovitz J., Lanusse C. Sex-related differences in the gastrointestinal disposition of ivermectin in the rat: P-glycoprotein involvement and itraconazole modulation. J. Pharm. Pharmacol. 2006, 58:1055-1062.
35. Moreau J.P., Prost A., Prod'hon J. Essai de normalisation de la méthodologie des enquêtes clinico-parasitologiques sur l'onchocercose en Afrique de l'ouest. Med. Trop. (Mars.) 1978, 38:43-51.
36. Mössinger J., Schulz-Key H., Dietz K. Emergence of Onchocerca volvulus microfilariae from skin snips before and after treatment of patients with ivermectin. Trop. Med. Parasitol. 1988, 39:313-316.
37. Ndong T.B., Kane Y., Diouf E.H.M., Alvinerie M. Ivermectin in Senegalese peulh sheep: influence of sex on plasma disposition. Vet. Res. Commun. 2007, 31:739-747.
38. Okonkwo P.O., Ogbuokiri J.E., Ofoegbu E., Klotz U. Protein binding and ivermectin estimations in patients with onchocerciasis. Clin. Pharmacol. Ther. 1993, 53:426-430.
39. Osei-Atweneboana M.Y., Eng J.K.L., Boakye D.A., Gyapong J.O., Prichard R.K. Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study. Lancet 2007, 369:2021-2029.
40. Pacque M.C., Dukuly Z., Greene B.M., Munoz B., Keyvan-Larijani E., Williams P.N., Taylor H.R. Community-based treatment of onchocerciasis with ivermectin: acceptability and early adverse reactions. Bull. World Health Organ. 1989, 67:721-730.
41. Pérez R., Palma C., Cabezas I., Araneda M., Rubilar L., Alvinerie M. Effect of parasitism on the pharmacokinetic disposition of ivermectin in lambs. J. Vet. Med. 2006, 53:43-48.
42. Plaisier A.P., van Oortmarssen G.J., Remme J., Habbema J.D.F. The reproductive lifespan of Onchocerca volvulus in West African savanna. Acta Trop. 1991, 48:271-284.
43. Prod'hon J., Boussinesq M., Fobi G., Prud'hom J.M., Enyong P., Lafleur C., Quillévéré D. Lutte contre l'onchocercose par ivermectine: résultats d'une campagne de masse au Nord-Cameroun. Bull. World Health Organ. 1991, 69:443-450.
44. Remme J., Ba O., Dadzie K.Y., Karam M. A force-of-infection model for onchocerciasis and its applications in the epidemiological evaluation of the Onchocerciasis Control Programme in the Volta River basin area. Bull. World Health Organ. 1986, 64:667-681.
45. Remme J.H.F., Amazigo U., Engels D., Barryson A., Yameogo L. Efficacy of ivermectin against Onchocerca volvulus in Ghana. Lancet 2007, 370:1123-1124.
46. Royston P., Ambler G. Multivariable fractional polynomials. STATA Tech. Bull. 1998, 43:24-32.
47. Royston P., Ambler G., Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. Int. J. Epidemiol. 1999, 28:964-974.
48. Sauerbrei W., Royston P. Building multivariable prognostic and diagnostic models: transformation of the predictors by using fractional polynomials. J. R. Stat. Soc. A (Stat.) 1999, 162:71-94.
49. Schulz-Key H. Observations on the reproductive biology of Onchocerca volvulus. Acta Leiden. 1990, 59:27-43.
50. Sharkey I., Boddy A.V., Wallace H., Mycroft J., Hollis R., Picton S. Body surface area estimation in children using weight alone: application in paediatric oncology. Br. J. Cancer 2001, 85:23-28.
51. Shu E.N., Onwujekwe E.O., Okonkwo P.O. Do alcoholic beverages enhance availability of ivermectin?. Eur. J. Clin. Pharmacol. 2000, 56:437-438.
52. Soboslay P.T., Newland H.S., White A.T., Erttmann K.D., Albiez E.J., Taylor H.R., Williams P.N., Greene B.M. Ivermectin effect on microfilariae of Onchocerca volvulus after a single oral dose in humans. Trop. Med. Parasitol. 1987, 38:8-10.
53. Taylor H.R., Greene B.M. The status of ivermectin in the treatment of human onchocerciasis. Am. J. Trop. Med. Hyg. 1989, 41:460-466.
54. Toutain P.L., Upson D.W., Terhune T.N., Mckenzie M.E. Comparative pharmacokinetics of doramectin and ivermectin in cattle. Vet. Parasitol. 1997, 72:3-8.
55. Walker M., Hall A., Anderson R.M., Basáñez M.G. Density-dependent effects on the weight of female Ascaris lumbricoides infections of humans and its impact on patterns of egg production. Parasit. Vectors 2009, 10:11.
56. Whitworth J.A.G., Gemade E.I.I. Independent evaluation of onchocerciasis rapid assessment methods in Benue State, Nigeria. Trop. Med. Int. Health 1999, 4:26-30.
57. Wildenburg G., Darge K., Knab K., Tischendorf F.W., Bonow I., Büttner D.W. Lymph nodes of onchocerciasis patients after treatment with ivermectin: reaction of eosinophil granulocytes and their cationic granule proteins. Trop. Med. Parasitol. 1994, 45:87-96.
58. World Health Organization, 1992. Methods for community diagnosis of onchocerciasis to guide ivermectin based control in Africa. Report of an informal consultation. Ouagadougou, November 19-21, 1991. Document TDR/TDE/ONCHO/92.2.